Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Invested Capital (2016 - 2025)

Lexaria Bioscience's Invested Capital history spans 11 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 51.85% year-over-year to $4.5 million; the TTM value through Nov 2025 reached $4.5 million, down 51.85%, while the annual FY2025 figure was $3.0 million, 60.97% down from the prior year.
  • Invested Capital for Q4 2025 was $4.5 million at Lexaria Bioscience, up from $3.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $13.1 million in Q3 2021 and bottomed at $2.7 million in Q3 2023.
  • The 5-year median for Invested Capital is $7.2 million (2022), against an average of $7.5 million.
  • The largest annual shift saw Invested Capital soared 518.83% in 2021 before it crashed 64.89% in 2023.
  • A 5-year view of Invested Capital shows it stood at $11.5 million in 2021, then crashed by 48.28% to $5.9 million in 2022, then plummeted by 43.14% to $3.4 million in 2023, then surged by 178.53% to $9.4 million in 2024, then crashed by 51.85% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Invested Capital are $4.5 million (Q4 2025), $3.0 million (Q3 2025), and $5.6 million (Q2 2025).